Table 2. Feasibility; treatment cycles delivered.
|
Preoperative (n=43) |
Postoperative (n=43) |
|||
|---|---|---|---|---|
| Chemotherapy fully evaluable patients (ITT) | FLO (n=22) | FLOT (n=21) | FLO (n=22) | FLOT (n=21) |
|
Cycles received | ||||
| 4 | 90% | 85% | 27% | 24% |
| 3 | 5% | 10% | — | 14% |
| 2 | — | — | 14% | 5% |
| 1 | 5% | 5% | 9% | — |
| 0 |
— |
— |
27% |
29% |
|
Percentage of intended dose delivered (per evaluable patient, ITT)a | ||||
| Docetaxel | — | 100% | — | 68.5% |
| Oxaliplatin | 100% | 98.5% | 74.7% | 50.3% |
| 5-Fluorouracil | 100% | 100% | 75.0% | 75.1% |
Abbreviations: FLO=oxaliplatin, fluorouracil; FLOT=fluorouracil, oxaliplatin, docetaxel; ITT=intention-to-treat.
a
The sum of the planned doses for all planned cycles compared with the sum of the delivered doses for all 43 patients.